. .
.
. Mayo Clinic Health Solutions
.
. .
.
Search:
Browse Categories:
  arrow Research Tools
arrow
  arrow Diagnostics
arrow
  arrow Therapeutics
arrow
  arrow Medical Devices
arrow
  arrow Electronic Devices
arrow
  arrow Software
arrow
  arrow All Listings
arrow
arrow
  Home
arrow
  About Us
arrow
  Contact Us
arrow
arrow
  Go to mayoclinic.org
arrow
  Go to Research at Mayo Clinic
arrow
Mayo Clinic Technology
.

Stably Transfected Cell Lines Expressing APPwt or Alkaline Phosphatase-APP105 Fusion that Produce Extremely High Levels of Abeta42

Reference #:

2005-107

Inventors/Contributors

Todd E. Golde, M.D., Thomas B. Ladd, Thomas L. Kukar, Ph.D., Marjorie J. Rochette, Karen R. Jansen-West, B.A.

Description

These cell lines express a protein (APP) that is cleaved to form the Amyloid beta protein (Abeta) deposited in Alzheimer's disease. Compared to other cell lines they produce extremely high levels enabling routine detection of even minor Abeta species (e.g. Abeta 42) in as little as 4-6 hours. Lysates and subcellular fractions from these cells can also be used for in vitro gamma-secretase activity assays.

Patent Status

None

Contact

Susan L. Stoddard, Ph.D., Licensing Manager
sstoddard@mayo.edu

Mayo Foundation for Medical Education and Research
Office of Technology Commercialization
Centerplace 4
200 First Street SW
Rochester, MN 55905

Phone: (507) 284-1222
Fax: (507) 284-5410